Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas
- PMID: 7585621
Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas
Abstract
Immunohistochemical screening of pancreatic adenocarcinomas from 24 different patients and 9 pancreatic carcinoma cell lines revealed variant CD44 expression in all specimens tested. In contrast to normal pancreatic tissue, carcinomas were strongly positive for epitopes encoded by variant exons v5, whereas v6 was expressed on carcinoma cells as well as normal ductal pancreatic cells. Analysis of RNA expression revealed clear differences between normal pancreatic tissue and tumor specimens. In normal pancreas, v6 and v3 solely and one major chain consisting of v6-v10 were expressed, whereas in pancreatic carcinoma, multiple splice variants were detected. In about 80% of all carcinoma cases and all cell lines tested, the exon v5 appeared in the chain containing at least v4-v10. These data thus far suggest that not the presence alone but the chain composition of the CD44 variant chains could be important for their altered function because one of the major differences between normal and cancer tissue is the linkage of CD44v5 to the CD44v6-containing chain.
Similar articles
-
Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa.Cancer Res. 1993 Sep 15;53(18):4197-203. Cancer Res. 1993. PMID: 7689929
-
Expression of CD44 in duct cell carcinomas and in intraductal neoplasms of the pancreas.Anticancer Res. 1997 Jan-Feb;17(1A):215-9. Anticancer Res. 1997. PMID: 9066654
-
CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma.Cancer Res. 1995 May 1;55(9):1831-5. Cancer Res. 1995. PMID: 7537174
-
CD44 in normal human pancreas and pancreatic carcinoma cell lines.Teratog Carcinog Mutagen. 2001;21(1):97-106. Teratog Carcinog Mutagen. 2001. PMID: 11135324
-
Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors.Cancer Res. 1994 Feb 15;54(4):981-6. Cancer Res. 1994. PMID: 7508823
Cited by
-
The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer.Stem Cells Int. 2016;2016:2087204. doi: 10.1155/2016/2087204. Epub 2016 Apr 21. Stem Cells Int. 2016. PMID: 27200096 Free PMC article. Review.
-
Molecular studies into the role of CD44 variants in metastasis in gastric cancer.Mol Pathol. 1999 Feb;52(1):25-8. doi: 10.1136/mp.52.1.25. Mol Pathol. 1999. PMID: 10439835 Free PMC article. Review.
-
Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs).J Proteome Res. 2012 Nov 2;11(11):5556-63. doi: 10.1021/pr300483r. Epub 2012 Oct 11. J Proteome Res. 2012. PMID: 22985314 Free PMC article.
-
Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential.J Exp Clin Cancer Res. 2023 Oct 26;42(1):282. doi: 10.1186/s13046-023-02858-z. J Exp Clin Cancer Res. 2023. PMID: 37880792 Free PMC article. Review.
-
Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers.J Histochem Cytochem. 2011 Apr;59(4):441-55. doi: 10.1369/0022155411398275. J Histochem Cytochem. 2011. PMID: 21411814 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous